Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate-to-severe atopic dermatitis
| dc.rights.license | open | en_US |
| dc.contributor.author | STAUMONT-SALLÉ, D. | |
| dc.contributor.author | BARBAROT, S. | |
| dc.contributor.author | BOUAZIZ, J.D. | |
| dc.contributor.author | CHAN, C. | |
| dc.contributor.author | CLIBBORN, C. | |
| dc.contributor.author | DU-THANH, A. | |
| dc.contributor.author | FEENEY, C. | |
| dc.contributor.author | LEJEUNE, A. | |
| dc.contributor.author | MISERY, L. | |
| dc.contributor.author | NOSBAUM, A. | |
| hal.structure.identifier | Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept] | |
| dc.contributor.author | SENESCHAL, Julien | |
| dc.contributor.author | SORIA, A. | |
| dc.contributor.author | ZHANG, F. | |
| dc.date.accessioned | 2024-06-10T08:13:10Z | |
| dc.date.available | 2024-06-10T08:13:10Z | |
| dc.date.issued | 2023 | |
| dc.identifier.issn | 2768-6566 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/200357 | |
| dc.description.abstractEn | Background: Eosinophilia is common in patients with atopic dermatitis (AD). Abrocitinib, an oral Janus kinase-1 inhibitor and dupilumab, an anti–interleukin-4 receptor-α antibody, are approved for moderate-to-severe AD. Dupilumab has been associated with transient eosinophilia. Objectives: To assess the effect of abrocitinib and dupilumab on eosinophils in patients from the phase 3 JADE COMPARE (NCT03720470) and JADE EXTEND (NCT03422822) trials. Methods: In JADE COMPARE, patients received once-daily oral abrocitinib (200/100 mg), placebo or subcutaneous dupilumab (300 mg, biweekly) with background topical therapy. In the ongoing long-term JADE EXTEND study (Data cutoff: April 22, 2020), dupilumab-treated patients from JADE COMPARE received once-daily abrocitinib (200/100 mg) with background topical therapy. The proportion of patients with eosinophilia and hypereosinophilia, and association of eosinophilia with clinical efficacy was assessed. Adverse events (AEs) were also assessed. Results: Of the 837 patients in JADE COMPARE, 58 (25.7%), 47 (19.7%) and 51 (21.1%) had eosinophilia at baseline in the abrocitinib 200 mg, abrocitinib 100 mg and dupilumab groups, respectively. At Week 16, eosinophilia decreased with abrocitinib 200 mg (9.3%) and abrocitinib 100 mg (19.0%) but not dupilumab (21.5%); no cases of hypereosinophilia were observed with abrocitinib 200 mg compared with abrocitinib 100 mg (1.9%) and dupilumab (2.3%). Decreases in median eosinophil counts were greater with abrocitinib 200 mg (difference, −100/mm3) and abrocitinib 100 mg (−70/mm3) than dupilumab (+25/mm3) or placebo (+30/mm3) at Week 16. Similar trends were observed in patients with comorbid asthma and allergic rhinitis. Eosinophilia decreased from baseline to Week 12 in dupilumab-treated patients who switched to abrocitinib in JADE EXTEND. Decreased eosinophil counts with abrocitinib correlated positively with improvements in AD severity, itch and sleep loss. No eosinophilia-associated AEs occurred. Conclusions: Abrocitinib decreased eosinophilia in patients with moderate-to-severe AD who had baseline eosinophilia. Resolution of eosinophilia was associated with abrocitinib clinical efficacy. © 2023 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.subject.en | Atopic dermatitis | |
| dc.subject.en | Clinical trials | |
| dc.subject.en | eosinophil disorders | |
| dc.title.en | Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate-to-severe atopic dermatitis | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1002/jvc2.192 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Immunologie | en_US |
| bordeaux.journal | JEADV Clinical Practice | en_US |
| bordeaux.page | 518-530 | en_US |
| bordeaux.volume | 2 | en_US |
| bordeaux.hal.laboratories | ImmunoConcEpT - UMR 5164 | en_US |
| bordeaux.issue | 3 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | CNRS | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | false | |
| dc.rights.cc | CC BY-NC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=JEADV%20Clinical%20Practice&rft.date=2023&rft.volume=2&rft.issue=3&rft.spage=518-530&rft.epage=518-530&rft.eissn=2768-6566&rft.issn=2768-6566&rft.au=STAUMONT-SALL%C3%89,%20D.&BARBAROT,%20S.&BOUAZIZ,%20J.D.&CHAN,%20C.&CLIBBORN,%20C.&rft.genre=article |
